Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.
Ragonese, M., Grottoli, S., Maffei, P., Alibrandi, A., Ambrosio, M.R., Arnaldi, G., et al. (2018). How to improve effectiveness of pegvisomant treatment in acromegalic patients. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 41(5), 575-581 [10.1007/s40618-017-0773-0].
How to improve effectiveness of pegvisomant treatment in acromegalic patients
Arnaldi, G;
2018-01-01
Abstract
Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
s40618-017-0773-0.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
524.46 kB
Formato
Adobe PDF
|
524.46 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
